Margaret Donovan, Senior Product Manager, Seer
Asim Siddiqui, Senior VP of Research, Seer
0:00 New tech no longer a trade-off between depth and sample size
5:12 What will this landmark paper mean for patients?
12:05 How does Seer’s technology work?
21:17 How many proteoforms are there?
28:13 Now similar to cfDNA revolution
It’s a thrilling time to be in proteomics. Today we discuss a recent paper in PLOS One demonstrating how new technology has revealed a novel biomarker for non-small cell lung cancer previously undetected by other methods. The paper could be a model for new proteomics research going forward. Our guests are Margaret Donovan, Product Marketing Manager, and Asim Siddiqui, Senior VP of Research, both at proteomics company, Seer.
“Historically the way in which we’ve been able to analyze the proteome has essentially meant you’re making trade-offs. You can either assess really deeply into the proteome with a small sample set or not so deep with a larger data set. With Seer’s technology, we have enabled both deep assessment of the proteome and the ability to see complexity with large datasets,” says Margaret.
Based on nanotechnology, Seer’s new platform is part of a new revolution in scaling up proteomics the way genomics scaled a generation ago. In the past, proteomics technologies were just seeing the overwhelming dominant proteoforms, say our guests, but now we are discovering millions of new proteoforms the way we began to discover millions of genomic variants. How many more proteoforms are there to discover? Lots more. Asim says proteomics is now where genomics was in the 1980s. However, because we learned so much in genomics, it will go much faster with the proteome.
To Margaret and Asim, the papers coming out in the field like the one we discuss today are similar to the cell-free DNA work that led to the prenatal diagnostics industry.